Company Description
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally.
The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older.
It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia.
The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021.
Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
| Country | United States |
| IPO Date | Sep 25, 2008 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Joshua R. Disbrow |
Contact Details
Address: 373 Inverness Parkway Englewood, Colorado United States | |
| Website | https://aytubio.com |
Stock Details
| Ticker Symbol | AYTU |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001385818 |
| CUSIP Number | 054754874 |
| ISIN Number | US0547548588 |
| Employer ID | 47-0883144 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joshua R. Disbrow | Chairman & Chief Executive Officer |
| Mark K. Oki CPA | Chief Financial Officer, Secretary & Treasurer |
| Greg Pyszczymuka | Chief Commercial Officer |
| Jarrett T. Disbrow Ph.D. | Chief Business Officer |
| Margaret Cabano | Vice President of Operations |
| Russ McMahen | Senior Vice President of Research & Development |
| Ryan J. Selhorn CPA | Executive Vice President of Finance & Business Optimization |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 02, 2025 | 4 | Filing |
| Dec 04, 2024 | 8-K | Current Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 4 | Filing |
| Nov 13, 2024 | 3 | Filing |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 08, 2024 | 4 | Filing |
| Nov 08, 2024 | 4 | Filing |
| Nov 08, 2024 | 4 | Filing |